PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION

PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION

The aim – assess the clinical advantages and economic burden of various treatment strategies in patients with hemophilia A in the Russian Federation and propose the ways of optimizing this area of medical care.Materials and methods. A mathematical model describing the current (2017) approach to ther...

Full description

Bibliographic Details
Main Authors:	M. Yu. Frolov, V. A. Rogov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2018-02-01
Series:	Фармакоэкономика
Subjects:	hemophilia a prophylaxis personalized prophylaxis cost-effectiveness analysis pharmacoeconomics
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/212

Similar Items

Current Situation and Prospect of Pharmacoeconomic Evaluation of Hemophilia in China
by: LI Shunping, et al.
Published: (2022-10-01)

Prophylaxis in Hemophilia
by: Júlia Plentz Portich, et al.
Published: (2023-05-01)

Hemophilia in pediatric age
by: Cristina Elena Singer, et al.
Published: (2023-09-01)

PHARMACOECONOMIC ANALYSIS OF EFFICACY OF DIFFERENT MODES OF ANTIBIOTIC PROPHYLAXIS IN CHOLECYSTECTOMY
by: A. N. Poborskiy, et al.
Published: (2016-10-01)

Short-term intermittent prophylaxis post-intracranial hemorrhage in children with hemophilia
by: Novie Amelia Chozie, et al.
Published: (2022-05-01)

Pharmacoeconomics and Utilization of Intravenous Proton Pump Inhibitors in a Tertiary Care Hospital
by: Prerana Kadam, et al.
Published: (2022-10-01)

Current status of treatment and disease burden of a cohort of hemophilia B in China
by: Yiwen Huang, et al.
Published: (2024-01-01)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
by: Byung Suk Moon, et al.
Published: (2013-07-01)

Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center
by: Qianqian Mao, et al.
Published: (2024-12-01)

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS
by: M. Yu. Frolov, et al.
Published: (2017-05-01)

Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B
by: Djambas Khayat C
Published: (2016-11-01)

Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
by: Jing Sun, et al.
Published: (2021-06-01)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

Changes over the last two decades in Hemophilia A and B management in a Tertiary Care Pediatric Centre
by: M.P. Esposto, et al.
Published: (2024-09-01)

Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India
by: Tulika Seth, et al.
Published: (2023-12-01)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
by: Guoqing Liu, et al.
Published: (2022-10-01)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
by: Ricardo Mesquita Camelo, et al.
Published: (2023-12-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2022-12-01)

Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
by: Midori Shima
Published: (2020-05-01)

Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective
by: Daniela Paola Roggeri, et al.
Published: (2020-06-01)

Platelet function and microvesicle generation in patients with hemophilia A
by: Antonia Melero‐Amor, et al.
Published: (2021-03-01)

Sports and Children with Hemophilia: Current Trends
by: Lorenzo Moretti, et al.
Published: (2021-11-01)

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
by: Michael U. Callaghan, et al.
Published: (2022-08-01)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
by: Saunya Dover, et al.
Published: (2020-02-01)

Methodological quality and recommendations of hemophilia clinical practice guidelines: A scoping review
by: Carolina J. Delgado‐Flores, et al.
Published: (2023-07-01)

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
by: Tine M.H.J. Goedhart, et al.
Published: (2022-01-01)

Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single‐center experience in Bangladesh
by: Sanzina Sadia Tory, et al.
Published: (2024-02-01)

Appropriateness and pharmacoeconomics of surgical antimicrobial prophylaxis in open reduction internal fixation surgery practiced in a tertiary hospital compared to recommendations in the national center for disease control guidelines
by: Priyanka Kumari, et al.
Published: (2019-01-01)

CORRELATION OF THE PARAMETERS OF THROMBO-ELASTOGRAM WITH THE RESULTS OF COAGULATIOIN TESTS IN HAEMOPHILIA A PATIENTS DURING PROPHYLAXIS
by: V. V. Krasivska, et al.
Published: (2019-09-01)

Prophylaxis and hemophilia care in LATAM: Baring it all—Highlights from the CLAHT 2021 symposium
by: Giovanni G. DiMinno, et al.
Published: (2022-11-01)

Joining the patient on the path to customized prophylaxis: one hemophilia team explores the tools of engagement
by: Gue D, et al.
Published: (2015-12-01)

Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
by: Jennifer Stimec, et al.
Published: (2021-10-01)

Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
by: Bolívar Luis Díaz‐Jordán, et al.
Published: (2023-12-01)

Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19
by: Marina V. Zhuravleva, et al.
Published: (2023-02-01)

Aggressive Neuroblastoma in a Pediatric Patient with Severe Hemophilia A
by: Lidia Costa, et al.
Published: (2021-03-01)

Pharmacoeconomic particulars of ovaries cancer’s treatment
by: V N Zhurman, et al.
Published: (2015-06-01)

Pharmacoeconomics of Bronchial Asthma
by: Ivanova Zlatina I., et al.
Published: (2019-06-01)

Evaluation of efficacy of twice-weekly prophylactic treatment with BeneFIX® (recombinant factor IX) followed by once weekly in children with severe hemophilia B: Six-year data from a local registry
by: Rafal Raad Al-Janabi, et al.
Published: (2021-01-01)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
by: Runhui Wu, et al.
Published: (2021-08-01)